GSK_Annual_Report_2021

Financial Statements GlaxoSmithKline Pharmaceuticals Limited 174 (a) Equity share capital ( ` in lakhs) As at March 31, 2021 As at March 31, 2020 Balance at the beginning of the reporting period 169,40.60 169,40.60 Changes in equity share capital during the year - - Balance at the end of the reporting period 169,40.60 169,40.60 (b) Other equity ( ` in lakhs) Particulars Reserves and Surplus Items of Other comprehensive income Total Other Equity Capital reserve (i) General reserve (ii) Retained earnings (iii) Capital redemption reserve (iv) Remeasurements of the net defined benefit plans Balance as at April 1, 2020 1,70.97 778,50.29 875,51.81 2,62.00 (7,15.18) 1651,19.89 Total comprehensive income Profit for the year - - 358,14.73 - - 358,14.73 Other comprehensive loss for the year - - - - (2,04.84) (2,04.84) Transactions with owners of the company Dividend on equity shares ( ` 40 per share including special dividend of ` 20 per share) - - (677,62.41) - - (677,62.41) Balance as at March 31, 2021 1,70.97 778,50.29 556,04.13 2,62.00 (9,20.02) 1329,67.37 Balance as at April 1, 2019 1,70.97 778,50.29 1190,76.95 2,62.00 (3,17.89) 1970,42.32 Total comprehensive income Profit for the year - - 93,20.46 - - 93,20.46 Other comprehensive loss for the year - - - - (3,97.29) (3,97.29) Transactions with owners of the company Dividend on equity shares ( ` 20 per share) - - (338,81.21) - - (338,81.21) Dividend distribution tax - - (69,64.38) - - (69,64.38) Balance as at March 31, 2020 1,70.97 778,50.29 875,51.81 2,62.00 (7,15.18) 1651,19.89 (i) Capital reserve includes Central Government subsidy and capital profit on reissue of shares forfeited of erstwhile Burroughs Wellcome (India) Limited and is not available for distribution. (ii) General reserve represents the transfer of profits from retained earnings. (iii) Retained earnings represents the cumulative profits of the Company which can be utilised in accordance with the provisions of the Companies Act, 2013. (iv) Capital redemption reserve is on account of buy back of equity shares and it is not available for distribution. Consolidated Statement of Changes in Equity for the year ended March 31, 2021 In terms of our report attached For Deloitte Haskins & Sells LLP For and on behalf of the Board of Directors Chartered Accountants R. S. Karnad Chairperson DIN: 00008064 S. Venkatesh Managing Director DIN: 07263117 Rupen K. Bhatt P. Thakur CFO & Whole-time Director DIN: 07971789 Partner D. Sundaram Audit Committee Chairman DIN: 00016304 A. Nadkarni Company Secretary FCS 10460 Mumbai, May 18, 2021 Mumbai, May 18, 2021